Clinical Trial Update: A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 study of PD 0332334 in Generalized Anxiety Disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: TERMINATED